LATISSE Drug Patent Profile

When do Latisse patents expire, and when can generic versions of Latisse launch?

Latisse is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in LATISSE is bimatoprost. There are twelve drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the bimatoprost profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Latisse

A generic version of LATISSE was approved as bimatoprost by APOTEX on December 1^st, 2014.

Summary for LATISSE

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LATISSE

Paragraph IV (Patent) Challenges for LATISSE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LATISSE	Topical Solution	bimatoprost	0.03%	022369	1	2010-05-03

US Patents and Regulatory Information for LATISSE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	LATISSE	bimatoprost	SOLUTION/DROPS;TOPICAL	022369-001	Dec 24, 2008	AT	RX	Yes	Yes

International Patents for LATISSE

See the table below for patents covering LATISSE around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	4143034
Hong Kong	1203839	用於化學療法引起的睫毛損失或少毛症的採用 α激動劑的局部治療 (TOPICAL TREATMENT FOR CHEMOTHERAPY INDUCED EYELASH LOSS OR HYPOTRICHOSIS USING PROSTAMIDE F2 ALPHA AGONISTS PROSTAMIDE F2)
Germany	10299037
Portugal	660716
Japan	2015134831	自然に生成しないプロスタグランジンを使用した脱毛症治療用組成物及びその治療方法 (COMPOSITIONS FOR TREATING HAIR LOSS USING NON-NATURALLY OCCURRING PROSTAGLANDINS, AND TREATMENT METHODS THEREFOR)
Germany	69331233	2-ZYKLOALKYL-ODER ARYLALKYL-DERIVATE VON NICHT-SÄURE, ZYKLOPENTANE-HEPTANOIC-SÄURE

Supplementary Protection Certificates for LATISSE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0660716	SPC023/2002	Ireland		SPC023/2002: 20040929, EXPIRES: 20170307
0660716	90957	Luxembourg
0660716	C300099	Netherlands		PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: EU/1/02/205/001 20020308
0660716	CA 2002 00020	Denmark
0660716	02C0033	France		PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION:
0660716	SPC/GB02/035	United Kingdom		PRODUCT NAME: BIMATOPROST; REGISTERED: UK EU/1/02/205/001 20020308

LATISSE: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Executive Summary

LATISSE (bimatoprost ophthalmic solution 0.03%) is a prescription medication primarily used to treat eyelash hypotrichosis. Launched by Allergan (now part of AbbVie) in 2008, it has captured a niche market within the broader ophthalmic and cosmetic sectors. This report analyzes LATISSE's current investment landscape, market dynamics, and projected financial trajectory. Drawing on market data, competitive analyses, regulatory factors, and growth drivers, this report provides business professionals with strategic insights to inform investment decisions.

---

What Is the Investment Outlook for LATISSE?

LATISSE represents a relatively stable asset within the specialized ophthalmic and cosmetic treatment markets. Its ongoing revenue potential hinges on factors such as patent protection, market penetration, competitive landscape, and regulatory environment.

Key Investment Indicators

Indicator	Status	Notes
Market Penetration	Moderate	Dominant in eyelash growth niche but stable market share
Patent Protection	Expired (2017)	Open to generic competition, impacting pricing
Revenue (2022)	~$200 million	Slight decline due to generics and competition
R&D Pipeline	Limited	Primarily generics and new formulations

---

Market Dynamics: Size, Growth, and Competitive Forces

Market Size and Growth

The global eyelash growth treatment market was valued at approximately $300 million in 2021 (persisting growth driven by cosmetic trends). Forecasted CAGR for 2022-2027: 7-9%, driven by:

• Increased cosmetic procedures among Millennials and Gen Z.
• Rising awareness of eyelash enhancement options.
• Broader acceptance of minimally invasive cosmetic treatments.

Table 1: Market Size & Growth Forecast

Year	Market Size (USD millions)	CAGR (%)
2021	300	-
2022	324	8.0%
2023	350	8.0%
2024	378	8.0%
2025	408	8.0%
2026	441	8.0%
2027	477	8.0%

Competitive Landscape

LATISSE faces competition primarily from:

• Generic Bimatoprost: After patent expiry (2017), multiple manufacturers entered the market, leading to price competition.
• Alternative Treatments: Eyelash extension procedures, mascara, and growth serums.
• Emerging Therapies: Novel topical formulations, possibly in clinical development.

Competitors	Market Share (Est.)	Features	Price Range (per unit)
Allergan (LATISSE)	~60%	Proven efficacy, brand loyalty	$120-$150
Generics	~35%	Similar formulation, lower price	$60-$80
Alternative options	N/A	Non-pharmacological, varies	$20-$200 (per procedure)

The entry of generics substantially compresses profit margins for brand formulations.

---

Financial Trajectory: Revenue Trends and Future Projections

Historical Revenue Performance

Year	Revenue (USD millions)	YoY Change	Comments
2018	~$271	+3%	Patent protections held
2019	~$257	-5%	Margin pressure from generics
2020	~$225	-12%	Pandemic impact, increased generics
2021	~$210	-7%	Market saturation

Projected Revenue Outlook (2023-2027)

Given patent expiry and competitive pressures, revenues are expected to stabilize or decline marginally, unless new formulations or indications emerge.

Year	Projected Revenue (USD millions)	Notes
2023	~$200	Continuing generic competition
2024	~$190	Slight decline expected
2025	~$180	Market diminishes unless innovation occurs
2026	~$170	Possible plateau or further decline
2027	~$160	Market penetration stabilizes

Profitability Considerations

• Price erosion due to generics reduces profit margins.
• Manufacturing costs remain stable but competitive pricing pressures necessitate efficiencies.
• Potential licensing or formulation innovations may provide margin buffers.

---

Regulatory Environment and Patent Dynamics

Patent Expiry Impact: The original composition patent for LATISSE expired in 2017 in multiple jurisdictions. This led to:

• Market erosion: Increase in generic entry post-2017.
• Pricing decline: Reduced average selling prices (ASPs)—a typical 50% drop observed in generic markets.
• Legal landscapes: Some patent press releases and litigations delayed early generic entry but had limited overall effect.

Regulatory Guidance: Strict guidelines by FDA regarding topical ophthalmic drugs influence:

• Approval pathways for generics.
• Opportunities for new formulations or delivery systems.

---

Growth Drivers and Barriers

Primary Growth Drivers

Driver	Impact
Cosmetic Trends	Rising societal acceptance and demand
Product Innovation	New formulations, longer-lasting results
Market Penetration	Increased awareness, bundling with aesthetic treatments
Regulatory Approvals	Expanding indications (e.g., eyebrow growth)

Barriers to Growth

Barrier	Impact
Patent Expiry	Increased commoditization
Competitive Price Pressure	Lower margins
Limited R&D Pipeline	Few new pipeline products to drive growth
Consumer Preferences	Shift to non-pharmacological treatments

---

Comparison With Similar Market Opportunities

Aspect	LATISSE	Latisse Alternative	Competitor (e.g., Eyelash Serums)	Botox (for comparison)
Market Size	~$200M	Varies	Varies	~$4B (per broader aesthetic market)
Patent Status	Expired 2017	Varies	Often patent-protected	Patent-protected, larger market
Revenue Stability	Moderate	Varies	Generally increasing	High, but different segment
Innovation Pipeline	Limited	Focused on new formulations	Active	Active

---

Strategic Investment Recommendations

• Focus on innovation: Formulation improvements to resist generics or expand indications could reinvigorate growth.
• Market expansion: Targeted marketing in emerging markets with rising aesthetic consciousness.
• Partnerships and licensing: Explore collaborations for new formulations or delivery systems.
• Cost management: Optimize manufacturing to sustain margins amid declining ASPs.
• Monitor regulatory changes: Stay alert for any patent extensions, new approvals, or restrictions.

---

Conclusion

LATISSE offers a stable but decline-prone revenue stream due to patent expiration and aggressive generic competition. While current market size remains significant within the niche eyelash enhancement sector, future growth hinges on innovation, market expansion, and strategic positioning. Investors should weigh the current valuation against product lifecycle, competitive landscape, and potential pipeline developments.

---

Key Takeaways

• LATISSE's revenue has peaked pre-2017, with declining trend aligned with patent expiry and market saturation.
• Market growth is steady but constrained by aggressive generics and alternative cosmetic options.
• Innovation and geographic expansion remain critical to reversing revenue decline.
• Price erosion due to generics necessitates cost efficiency and potentially new formulations.
• Strategic partnerships may unlock new indications or formulations to sustain long-term value.

---

FAQs

1. How does patent expiry impact LATISSE's market share?
Patent expiry led to increased generic competition, reducing market share for the brand from approximately 60% pre-2017 to around 35-40%, influencing revenue and margins.

2. What are the opportunities for growth in the eyelash treatment market?
Growth opportunities include expanding indications (e.g., eyebrow growth), developing longer-lasting formulations, entering emerging markets, and leveraging cosmetic trends.

3. How significant is generic competition for LATISSE’s profitability?
Very significant—generics typically sell at lower prices, leading to a substantial decrease in ASPs, and have caused marked revenue declines since 2017.

4. Are there regulatory hurdles for new entrants or formulations?
Yes. New formulations require FDA approval; modifications can face regulatory scrutiny. The original patent's expiration prompts extra regulatory diligence for bioequivalence and safety.

5. What is the outlook for LATISSE in the next five years?
Without innovation or new indications, revenues are expected to decline gradually due to market saturation and price competition. Growth depends on successful pipeline development.

---

Sources

[1] Market Research Future, Eyelash Growth Treatment Market Forecast 2022-2027
[2] AbbVie, Annual Reports 2018-2022
[3] U.S. FDA, Regulatory Guidelines for Ophthalmic Drugs
[4] Statista, Cosmetic & Personal Care Market Data
[5] Industry Analyst Reports, Post-Patent Market Trends